Create accountLogin

Recent searches

No recent searches

Search options

Not available on disabled.social.
disabled.social is one of the many independent Mastodon servers you can use to participate in the fediverse.
A place for people who are chronically ill, mentally ill, disabled, and friends/families/allies to come together, meet, share knowledge and random banter, and just about anything else.

Administered by:

Server stats:

232
active users

disabled.social: AboutPrivacy policy

Mastodon: AboutGet the appKeyboard shortcutsView source codev4.3.6

Public
Tom Kindlon

Gut microbiota from patients with cause alterations in mice that resemble post- symptoms

shorturl.at/ipuvH

“we report the gut microbiota of subjects had a remarkable predominance of Enterobacteriaceae strains with an antibiotic-resistant phenotype compared to healthy controls. Additionally, short-chain fatty acid (SCFA) levels were reduced in feces”

@longcovid
@covid19

1/

Tom Kindlon

2/

“Fecal transplantation from subjects to germ-free mice led to lung inflammation & worse outcomes during pulmonary infection by multidrug-resistant Klebsiella pneumoniae. transplanted mice also exhibited poor cognitive performance. Overall, we show prolonged impacts of infection on the gut microbiota that persist after subjects have cleared the virus”

@longcovid
@covid

Sep 10, 2023, 03:36 PM·Public·Mastodon for iOS
6boosts·4favorites
Public
Rhyothemis

@tomkindlon @longcovid @covid

A stool microbiome test showed my daughter had Klebsiella overgrowth a few months after her Celiac diagnosis in 2019. She probably has POTS and also has some ME-like symptoms, but relatively mild. Her functional doctor tried Bactrim but she had an allergic reaction.

This article* from 2022 on use of phage therapy for Klebsiella in IBD is interesting, but how long will it be before people can actually access it? The article says a Phase II trial is planned, but I can't find any information on it.**

* news article:
sciencedaily.com/releases/2022

** link to the lab's clinical trial page:
weizmann.ac.il/Human_Research/

ScienceDailyPhage combination therapy can precisely target IBD-related gut bacteria without harming helpful microbesFor the first time, scientists have designed a phage combination therapy that can precisely target and suppress gut bacteria associated with inflammatory bowel diseases (IBD). The work showcases the possibility of using phages for treating diseases associated with gut microbiota.
Explore
About